Floatz logo

Vy-Aadc01

Brain Diseases

Neurocrine Biosciencesgene_therapyPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Brain Diseases cohort.

Asset / SponsorPhaseRating
Galantamine Hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3B
Donanemab
Eli Lilly and Company
Phase 3B
Fremanezumab
Hospital Clínico Universitario de Valladolid
Phase 4B
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4B
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4B

View all 43 →

Same molecule, other indications

Vy-Aadc01 is also rated in:

Parkinson diseaseDormant
CCC
Indicative ·
52 / 100
View asset →
basal ganglia disorderDormant
CC
Indicative ·
47 / 100
View asset →
movement disorderDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →